| 228.74 -0.16 (-0.07%) | 12-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 267.42 | 1-year : | 312.35 |
| Resists | First : | 228.96 | Second : | 267.42 |
| Pivot price | 224.16  |
|||
| Supports | First : | 218.33 | Second : | 211.77 |
| MAs | MA(5) : | 228.74 | MA(20) : | 221.52 |
| MA(100) : | 210.94 |
MA(250) : | 192.53 |
|
| MACD | MACD : | 4.1  |
Signal : | 3.4 |
| %K %D | K(14,3) : | 98.6 |
D(3) : | 98.6 |
| RSI | RSI(14): 82.9 | |||
| 52-week | High : | 228.96 | Low : | 123.76 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SGEN ] has closed below upper band by 30.6%. Bollinger Bands are 149.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 229.27 - 230.4 | 230.4 - 231.32 |
| Low: | 225.54 - 227.11 | 227.11 - 228.39 |
| Close: | 226.56 - 228.92 | 228.92 - 230.83 |
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Thu, 18 Apr 2024
Seagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated Nod - Yahoo Movies Canada
Thu, 14 Dec 2023
Pfizer Completes Acquisition of Seagen - Business Wire
Tue, 12 Dec 2023
Why Seagen (SGEN) Shares Are Gaining Today - Pfizer (NYSE:PFE) - Benzinga
Tue, 12 Dec 2023
Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing - Simply Wall St
Mon, 11 Dec 2023
Seagen lymphoma drug shows 100% progression free survival in Phase 2 trial - Seeking Alpha
Fri, 01 Dec 2023
Seagen's (SGEN) Combo Drug Expanded-Use sBLA Gets Priority Tag - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 189 (M) |
| Shares Float | 130 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 88.8 (%) |
| Shares Short | 9,580 (K) |
| Shares Short P.Month | 10,420 (K) |
| EPS | -4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.52 |
| Profit Margin | -32.7 % |
| Operating Margin | -35.3 % |
| Return on Assets (ttm) | -13 % |
| Return on Equity (ttm) | -28 % |
| Qtrly Rev. Growth | 27.1 % |
| Gross Profit (p.s.) | 1.1 |
| Sales Per Share | 12.19 |
| EBITDA (p.s.) | -3.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -540 (M) |
| Levered Free Cash Flow | -277 (M) |
| PE Ratio | -57.19 |
| PEG Ratio | 0.5 |
| Price to Book value | 16.91 |
| Price to Sales | 18.76 |
| Price to Cash Flow | -79.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|